PANEL No.2 -- THE RESEARCH RECORD
TB-500 research: the mechanism, the figures, and the line between fragment and full-length protein.
Actin sequestration is the engine. The repair effects are large and reproducible in animals. The identity caveat runs through all of it.
How Does TB-500 Work?
TB-500 research begins at the cytoskeleton. The fragment carries thymosin beta-4's WH2-type actin-binding motif, and the parent protein's mechanism is well characterized: X-ray crystallography of a gelsolin-domain-1–thymosin-beta-4 hybrid bound to actin (resolved to 2 Å) established that thymosin beta-4 forms a one-to-one complex with G-actin and sequesters the monomer by capping both of its ends, preventing polymerization [1].
That buffered pool of unpolymerized actin is what lets cells remodel their cytoskeleton on demand — to migrate, to form new vessels, to survive stress. In injury models the protein is associated with accelerated cell migration, angiogenesis, anti-inflammatory and anti-apoptotic signaling, reduced scar-forming myofibroblasts, and recruitment of progenitor cells [5]. Whether the isolated Ac-LKKTETQ 7-mer reproduces all of that at research doses is the open question controlled human trials have not answered.
TB-500 and Thymosin Beta-4: Fragment vs Full-Length Protein
Thymosin beta-4 is a ~4963 Da, 43-residue protein. TB-500 is the ~889 Da heptapeptide Ac-LKKTETQ cut from residues 17 to 23 of it [1]. They are not the same molecule, and the distinction is the single most important thing to carry into every figure below.
In commerce and in the analytical and anti-doping literature, "TB-500" denotes the heptapeptide. In the efficacy literature — the wound, stroke, cardiac, and fibrosis studies that the recovery rationale rests on — the molecule studied is almost always full-length thymosin beta-4 [5]. One consequence is biochemical: the full-length protein can be cleaved at its N-terminus to release Ac-SDKP, an anti-fibrotic, pro-angiogenic peptide — but Ac-SDKP comes from the opposite end of the protein and is not generated by the C-terminal-region TB-500 fragment. So even some of thymosin beta-4's own activity is, by construction, unavailable to the 7-mer.
TB-500 Benefits Observed in Research Models
The TB-500 benefits reported in the literature are, precisely stated, the effects of thymosin beta-4 in specified species and models — not demonstrated human outcomes.
Wound repair is the best-documented. In rat full-thickness wounds, thymosin beta-4 increased re-epithelialization by 42% at four days and up to 61% at seven days versus saline, increased wound contraction by at least 11% by day seven, and raised collagen deposition and angiogenesis [3]. Cardiac repair is the marquee result: thymosin beta-4 formed a complex with PINCH and integrin-linked kinase, activated the survival kinase Akt, and after coronary artery ligation in mice enhanced early cardiomyocyte survival and improved cardiac function [2]. A 2012 review consolidates the rest — actin binding, cell mobilization, fewer myofibroblasts and less scarring, anti-inflammatory and angiogenic activity — as the basis for clinical development in dermal wounds, corneal injury, and heart and CNS repair [5]. Each of these used full-length thymosin beta-4.
Recent thymosin beta-4 research, 2023-2026
The literature has not gone quiet. A 2024 study found that thymosin beta-4 promoted Mauthner-axon regeneration in zebrafish by facilitating actin dynamics — a clean tie back to the core mechanism, and directly relevant to this domain's neuro lens [11]. A 2024 paper linked thymosin beta-4's therapeutic effects to specialized pro-resolving pathways, situating it within inflammation-resolution biology [13]. A 2023 genetic study showed that targeted deletion of thymosin beta-4 in hepatic stellate cells ameliorated liver fibrosis — a useful reminder that the protein's role is cell-specific and not uniformly beneficial [12]. Delivery-system work continued too: a 2025 thymosin-beta-4-exosome hydrogel improved vascularized wound repair [14], and a 2024 rat study found thymosin beta-4 improved cutaneous-flap survival via Wnt/β-catenin signaling [15].
The through-line is consistent and the framing is honest. A 2026 sports-medicine review lists TB-500 and thymosin beta-4 among unapproved peptides with favorable animal repair data but scarce human safety evidence, and notes such compounds operate largely outside regulatory oversight [10].
What Is TB-500 Used For in Research?
Thymosin beta-4 and its actin-binding region have been studied in animal and topical-human models for wound healing, soft-tissue and ligament repair, cardiac protection, angiogenesis, anti-fibrotic remodeling, and neurological recovery [5]. Efficacy of the isolated heptapeptide in humans is unproven [10].
Are There Human Clinical Trials on TB-500?
No completed controlled clinical trials of the TB-500 heptapeptide exist for any indication [10]. Human data are limited to full-length thymosin beta-4: a randomized, placebo-controlled Phase 1 intravenous safety study in healthy volunteers [6], and topical ophthalmic (RGN-259) dry-eye and corneal-healing work [9].
Does TB-500 Help Wound Healing?
In rat full-thickness and corneal-injury models, thymosin beta-4 accelerated re-epithelialization, increased wound contraction, and raised collagen deposition and angiogenesis; as little as ~10 pg stimulated keratinocyte migration [3]. Topical human venous-ulcer and dry-eye trials used the full-length protein (RGN-259), not the TB-500 fragment [9].
How Long Does TB-500 Take to Work for Injury Healing?
Timelines come only from animal models. In a rat full-thickness wound study, thymosin beta-4 increased re-epithelialization by 42% at four days, rising to 61% by seven days versus saline [3]. No validated human healing timeline exists for the fragment [10].
Can TB-500 Help With Tendon and Ligament Repair?
The connective-tissue rationale rests on a small set of animal findings: thymosin beta-4's documented roles in cell migration, angiogenesis, and reduced scarring across repair models [5]. Controlled human tendon or ligament data for TB-500 are not available, and the 2026 review classes it among unapproved recovery peptides with scarce human evidence [10].
Does TB-500 Affect the Heart?
In mice, thymosin beta-4 activated the PINCH-ILK-Akt survival pathway and, after coronary artery ligation, enhanced early cardiomyocyte survival and improved cardiac function [2]. Counter-evidence exists, so the cardiac picture is mixed and entirely preclinical for the fragment [5].
Does TB-500 Promote Angiogenesis?
Thymosin beta-4 promotes endothelial migration and new-vessel formation in animal and biomaterial models, which aids repair [5][14]. The same pro-angiogenic activity underlies a theoretical tumor-angiogenesis concern, because it could in principle support tumor progression [10].
Does TB-500 Reduce Inflammation?
Full-length thymosin beta-4 suppresses NF-κB and IL-8 signaling in vitro and has reduced fibrosis in liver, renal, and pulmonary animal models; recent work links its effects to pro-resolving pathways [13]. These are mechanistic and preclinical findings, not human anti-inflammatory claims.